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Simple Summary: There is growing international interest in adopting a risk-based approach to breast
cancer screening, where an individual’s risk would inform screening practices. It has been suggested
that primary care will contribute to the delivery of this service by conducting risk assessment and
providing primary prevention advice. The aim of our review was to understand what primary care
providers think and feel about performing these tasks by examining their attitudes and typical activity
in clinical practice (routine behaviours). The results suggest that primary care providers mainly
assess breast cancer risk by collecting family history information but feel less comfortable advising
on risk-reducing medications. Primary care will need to proactively assess breast cancer risk for
women to get the most benefit from risk-based screening and prevention. To promote risk assessment
and prevention activities, improved education/training and changes to resources (integrated risk
assessment tools, better patient materials etc.) will be necessary.
Abstract: Implementing risk-stratified breast cancer screening is being considered internationally. It
has been suggested that primary care will need to take a role in delivering this service, including
risk assessment and provision of primary prevention advice. This systematic review aimed to assess
the acceptability of these tasks to primary care providers. Five databases were searched up to July–
August 2020, yielding 29 eligible studies, of which 27 were narratively synthesised. The review was
pre-registered (PROSPERO: CRD42020197676). Primary care providers report frequently collecting
breast cancer family history information, but rarely using quantitative tools integrating additional
risk factors. Primary care providers reported high levels of discomfort and low confidence with
respect to risk-reducing medications although very few reported doubts about the evidence base
underpinning their use. Insufficient education/training and perceived discomfort conducting both
tasks were notable barriers. Primary care providers are more likely to accept an increased role in
breast cancer risk assessment than advising on risk-reducing medications. To realise the benefits
of risk-based screening and prevention at a population level, primary care will need to proactively
assess breast cancer risk and advise on risk-reducing medications. To facilitate this, adaptations to
infrastructure such as integrated tools are necessary in addition to provision of education.
Keywords: primary care; breast cancer; risk assessment; primary prevention; systematic review
1. Introduction
Population based screening programmes aim to detect asymptomatic cancers at an
earlier stage to reduce mortality rates and the need for aggressive treatments associated
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with long term morbidities [1]. A substantial reduction in breast cancer related mortality
has been observed since the introduction of mammographic screening programmes [2,3].
However, harms of breast cancer screening include overdiagnosis and false positive test
results. Overdiagnosis refers to the diagnosis of breast cancers via screening that would
never have caused any clinically apparent symptoms over the course of a person’s life-
time [4]. A false positive result is an abnormality on a screening test that necessitates
further investigations, ultimately ruling out the presence of cancer. Whether the benefits of
screening outweigh the known harms has been much debated [2,5].
Adopting an alternative risk-based approach to breast cancer screening has the poten-
tial to improve the benefit to harm ratio [6]. The development of risk algorithms, such as
the Gail and Tyrer–Cuzick models, has made estimation of an individual’s breast cancer
risk possible [7,8]. The provision of personalised breast cancer risk estimates would allow
screening and prevention services to be offered that are commensurate with the degree
of risk, thus improving benefit to harm ratios [9,10]. In the UK, the Predicting Risk of
Cancer at Screening (PROCAS) study demonstrated that breast cancer risk information can
be collected and communicated to women participating in a population-based mammo-
graphic screening programme [11]. International trials are currently ongoing to establish
the effectiveness of a risk-based screening regimen in comparison to standard screening
practices [12,13].
A key benefit of risk estimation is the ability to identify women at increased risk, afford-
ing them the opportunity to benefit from preventative strategies. There are two strategies
that have proven benefit in reducing breast cancer risk. The use of selective oestrogen
receptor modulators and aromatase inhibitors, commonly referred to as chemoprevention
or risk-reducing medication, have been shown to reduce breast cancer incidence [14,15].
Furthermore, evidence suggests 15–40% of breast cancers may be preventable by engaging
in health-related behaviours such as increased physical activity and reduced alcohol in-
take [16]. Clinical guidance acknowledges the need to discuss lifestyle related risk factors
in relation to breast cancer risk but the care setting where this discussion should take place
is not specified [17].
As the first point of healthcare contact for the general population, primary care has
been repeatedly identified as the most opportune setting to conduct breast cancer risk
assessment [18,19]. Secondly, primary care providers have a critical role in delivering
preventive health care services to the general population as evidenced by their current role
in assessment and management of cardiovascular and diabetes risk [20,21].
As the likely roles of primary care in delivering risk-based screening and prevention
will be risk assessment and provision of primary prevention advice including prescription
of risk-reducing medication, it is important to assess acceptability of these activities. Ac-
ceptability is increasingly being recognised as an important component of the feasibility
of complex interventions in guidance documents such as the Medical Research Council
(MRC) framework [22].
A previous review identified a considerable evidence base related to the acceptability
of primary care involvement in risk-based screening and prevention [19]. This review iden-
tified numerous barriers reported by primary care providers in relation to their proposed
roles which suggests concerns about the acceptability of this approach. However, the scope
of the review was limited as it did not examine key participant-reported evaluations of
acceptability, such as confidence, as recommended by an evidence-based framework of
acceptability [23]. Furthermore, the review did not quantify the strength of individual
barriers and facilitators nor examine potential sources of variation such as country and
healthcare specialty. The latter is important to investigate as countries vary substantially in
how primary healthcare is delivered, including differences in training requirements and
what types of providers are considered part of the primary care workforce [18]. Conse-
quently, implementation of risk-based screening and prevention will likely differ across
countries [19].
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The present systematic review aimed to provide a robust and in-depth examination of
acceptability beyond identification of barriers and facilitators. It achieves this by employ-
ing the theoretical framework of acceptability which recognises the value of participant-
reported evaluations of acceptability in addition to behavioural assessments [23]. However,
as primary care providers’ significant knowledge deficits in this area have been described
extensively in previous systematic reviews [19,24–26], the present review did not assess
the extent to which primary care providers understand breast cancer risk assessment and
management.
Specific objectives were to summarise the evidence base on:
a. ratings of acceptability (including, attitudes, opinions, beliefs, feelings, barriers or
facilitators) by primary care providers with respect to (1) breast cancer risk assessment
and (2) primary prevention advice
b. the performance of routine behaviours by primary care providers regarding (1) breast
cancer risk assessment and (2) primary prevention advice
c. sources of variation in acceptability and behaviours
2. Methods
The protocol of this systematic review was pre-registered in PROSPERO (CRD42020197
676) and follows the reporting guidelines detailed in the PRISMA statement [27]. The pro-
tocol covered both quantitative and qualitative literature but for reasons of space only the
quantitative findings are reported here.
2.1. Search Strategy
The following electronic databases were searched: MEDLINE, EMBASE, CINAHL
Plus, PsycINFO (each up to 10 July 2020) and ProQuest Dissertations & Theses Global
(up to 26 August 2020). Databases were searched from 1989 as the first breast cancer risk
model incorporating multiple breast cancer risk factors was published in this year [7].
Search terms were produced using medical subject headings (MeSH), other index terms,
keywords and appropriate synonyms (see Supplementary Material S1) and refined with
the input of a librarian with expertise in systematic review searching. The strategy was
tailored in accordance with the technical language of each database. The searches were
limited to articles for which the full text was available in English. Forward and backward
citation searches and a lead author search were performed for all included papers. Relevant
reviews were hand-searched and researchers with expertise in the area were contacted to
identify any additional articles not retrieved by the searches.
2.2. Eligibility Criteria
Studies were included in the review if they met the following criteria:
1. Healthcare professionals who provided primary care services. To account for variation
in professional roles between healthcare structures in different countries, samples
reported as being primary care providers were regarded as such. In ambiguous
cases, authors were contacted to clarify whether their samples provided primary
care services in line with the World Health Organisation’s definition [28]. Studies
conducted with both primary and secondary care providers were only included if it
was possible to separately identify those findings relevant to primary care providers.
2. Data had to be reported about risk assessment and/or providing primary prevention
advice in the context of breast cancer. Studies focusing on cancer risk or primary pre-
vention whereby data specific to breast cancer could not be extracted were excluded.
3. Either or both of the following:
(a) Acceptability defined as anticipated or experiential cognitive and emotional
responses. Studies had to report one or more of the following outcomes
using quantitative methodologies: attitudes, opinions (e.g., perceptions of
responsibility), beliefs, feelings (e.g., confidence), barriers or facilitators.
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(b) Routine behaviours defined as typical or regular activity in clinical practice.
Frequency of behaviours reported in a specific timeframe were not eligible for
inclusion. Hypothetical clinical scenarios/vignettes or reflections on previous
clinical cases were ineligible as these methods ascertain the action taken in a
specific situation which may not be indicative of routine behaviours.
4. Studies: Full empirical articles of any quantitative design published in the English lan-
guage. Grey literature including PhD theses, dissertations and unpublished research
were eligible for inclusion. Additionally, baseline surveys of intervention studies
designed to improve breast cancer risk assessment behaviours or provision of primary
prevention advice were included.
2.3. Selection and Coding of Studies
The search results were downloaded into Endnote and duplicates were removed. The
library was then uploaded to Rayyan [29] to complete screening. The first author screened
all titles and abstracts and a second reviewer (RH) independently screened 30% (k = 945)
of these (97% agreement). Full text articles were obtained for all records that appeared to
be eligible or could not be confidently excluded (k = 124). The first author read all full text
articles and assessed these against the eligibility criteria. A second reviewer (RH) read 50%
of the full text articles (k = 62) and disagreements regarding the eligibility of an article were
resolved by discussion. In ambiguous cases, additional reviewers were consulted (DF, SH)
and consensus was reached.
2.4. Data Extraction
Following full text review, detailed information on study characteristics (authors,
country, study design and outcome measures), sample characteristics (sample size, age
and sex) and outcome data relevant to the objectives were extracted by the first author for
all eligible articles. A second reviewer (RH) verified the data extraction by independently
extracting primary outcome data for 50% (15/29) of eligible articles.
2.5. Quality Assessment
The Mixed Methods Appraisal Tool (MMAT) was deemed most suitable for quality
assessment due to its demonstrated reliability and inclusion of quality criteria specifically
designed to appraise quantitative descriptive study designs such as surveys [30]. Criteria
were categorised as ‘yes’, ‘somewhat’, ‘no’ or ‘can’t tell’. The response option of ‘somewhat’
was added to reflect when a criterion had been partially fulfilled but lacked some key
indicators of quality. This enabled a more nuanced approach to quality appraisal. The
authors of the tool discourage the use of a scoring metric therefore a narrative description
of quality is provided.
In line with MMAT recommendation, two authors (SB and DF) discussed which
quality indicators were most important to consider for each criterion listed and following
this a coding scheme was devised and agreed upon. All studies were appraised using
the criteria for quantitative descriptive designs to assess the quality of the survey design
and outcome measures which were of most interest to the review. A 50% rate of response
was a priori regarded as satisfactory for avoidance of nonresponse bias, in line with
response rates observed in previously published provider surveys [31]. Two authors (SB
and RH) independently appraised the quality of the remaining studies. Reviewers met on
three separate occasions to check the reliability of decisions and any disagreements were
discussed and resolved. During these meetings, the coding scheme was also reviewed and
refined in line with discussions to ensure consistency and fairness in coding.
2.6. Synthesis of the Evidence
A meta-analysis was deemed inappropriate as studies varied widely in outcomes,
measurement scales and study populations. Instead, a narrative synthesis was conducted
with findings tabulated [32]. The outcomes from each study were organised into categories
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initially based on what the authors of each individual study stated the data was measuring
(i.e., barrier, facilitator, confidence etc.). Additional outcomes that had not been explicitly
measured as barriers or facilitators (e.g., beliefs, feelings, etc.) were reviewed and cate-
gorised as such depending on whether they could reasonably be considered to promote or
impede performance of the behaviour. For example, a negative affective attitude such as
discomfort was categorised as a barrier. Consensus was reached on these decisions through
discussion with additional reviewers (DF and SH). Supplementary Material S2 provides
full details of the outcomes included per study, the raw data extracted from each study,
and how each outcome was categorised.
To aid interpretation and allow meaningful patterns to be identified, outcomes were
categorised into broader themes depending on content (see Supplementary Material S2).
Initial themes were identified by the first author. These themes were then refined and
agreed upon following several rounds of consultation with additional reviewers (DF and
SH). The findings were synthesised across the included studies.
3. Results
3.1. Study Characteristics
The searches identified 6750 articles, of which 3164 remained after duplicates were
removed (Figure 1). A total of 29 studies were eligible for inclusion (see Supplementary
Table S1 for list of excluded studies and reasons). Years of publication ranged from 1997
to 2020. Twenty-seven studies were included in the synthesis. Two were excluded due to
using measurement scales that could not be meaningfully compared to other studies [33,34].
More than half of the included studies were conducted in the USA (k = 14) (Table 1). Sample
sizes ranged from 28 [35] to 1311 [36] individuals. The most commonly studied population
were physicians. The majority (24/27, 89%) of studies assessed at least one outcome
relevant to breast cancer risk assessment. In comparison, fewer studies assessed outcomes
pertinent to primary prevention (9/27, 33%). No studies investigating health-related
behaviours within the context of breast cancer risk were identified so primary prevention
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Table 1. Characteristics of studies included in the synthesis (n = 27).
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Notes. * Nippert et al. (2014)—France, the Netherlands, UK and Germany; Mainous et al. (2013)—USA and
Canada. 1 These studies recruited other professional groups in addition to physicians and nursing staff, namely
physician assistants, midwives and residents.
3.2. Perceived Practice Responsibilities with Respect to Both Risk Assessment and
Primary Prevention
Primary care providers’ perceptions of responsibility with respect to tasks implicated
in breast cancer risk assessment and primary prevention were examined in several studies.
Taking a family history was overwhelmingly perceived as a primary care responsibility
(88.8–98.1%; Table 2). Additionally, primary care providers readily identified counselling
about risk and providing follow up support post genetic testing as practice responsibilities.
In comparison, discussion of genetic testing and disclosure of results were less likely to
be perceived as primary care responsibilities. Inter-country differences were apparent in
a study that recruited participants from four European countries [37]. GPs from France
ascribed most practice responsibilities to themselves whereas GPs from the UK considered
genetic risk and genetic testing to be the responsibility of genetic specialists. The most com-
monly assumed responsibilities for primary prevention were writing ongoing prescriptions
for risk-reducing medications and initiating discussions about preventative measures.
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Table 2. Primary care providers’ perceived responsibilities in breast cancer risk assessment and primary prevention.
Tasks Percentage Reporting Primary Care Responsibility [Meanand Range Reported if Multiple Values] Associations with Perceived Roles
Breast cancer risk assessment
Taking or documenting a family history [31,38,39] 92.7 [89.0–98.0]
Providing counselling regarding familial risk [38,39] 83.0 [81.0–85.0]
Providing follow up support after genetic testing [37,38] 79.7 [66.8–92.5]
Country:
One study recruited participants from four European countries
(UK, France, Germany and the Netherlands). The majority of
GPs from all four countries agreed that providing support after
breast cancer testing was a primary care responsibility.
However, the proportions varied significantly; the highest
proportion was reported by the GPs from France (86.1%) and
the lowest by the GPs from the UK (57.2%) [37]
Obtaining informed consent before genetic testing [38,39] 77.3 [67.0–87.5]
Identifying families at risk [38,39] 72.0 [58.0–86.0]
Calculating breast cancer risk [31] 62.0
Informing about breast cancer genetic testing [37,39] 61.5 [47.0–76.0]
Country:
GPs from France were significantly more likely to assume
responsibility for informing patients about breast cancer
genetic testing in comparison to GPs from Germany, the
Netherlands and the UK (56.2% vs. 46.6%, 41.7% and 41.6%)
[37]
Counseling women about breast density [40] 43.0
Explaining the inheritance pattern of familial breast cancer [37] 42.7
Country:
GPs from France were significantly more likely to assume
responsibility for explaining the inheritance pattern of familial
breast cancer in comparison to GPs from Germany, the
Netherlands and the UK (63.6% vs. 30%, 49.7% and 33.8%) [37]
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Table 2. Cont.
Tasks Percentage Reporting Primary Care Responsibility [Meanand Range Reported if Multiple Values] Associations with Perceived Roles
Disclosing breast cancer genetic test results [37,39] 37.2 [27.4–47.0]
Country:
GPs from Germany were significantly more likely to assume
responsibility for disclosing breast cancer genetic test results in
comparison to GPs from France, the Netherlands and the UK
(43.7% vs. 23.5%, 11.6% and 16.9%) [37]
Primary prevention
Writing ongoing prescriptions for risk-reducing medications
[41] 97.9
Providing options for prevention and early detection of breast
cancer [38] 86.0
Initiating discussion of risk-reducing medications [41] 75.0
Writing first prescription for risk-reducing medications [41] 31.3
Breast cancer risk reduction with chemopreventive agents [31] 18.0
Sex:
Males more likely to agree that breast cancer risk reduction
with chemopreventive agents was a primary care provider’s
responsibility than females (28% compared to 10%) [31]
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4. Risk Assessment
4.1. Barriers and Facilitators
For conducting breast cancer risk assessment, the most commonly endorsed barriers
were insufficient education/training followed by discomfort discussing breast density and
performing the assessment (Table 3). The least frequently endorsed barriers included lack
of primary care responsibility and concern about the implications of risk assessment for
women with respect to causing unnecessary anxiety or impacting screening behaviour.
None of the included studies investigated factors that could help facilitate breast cancer
risk assessment behaviour.
4.2. Perceived Confidence
Primary care providers reported highest levels of confidence in taking a family history
(60.7–65.5%) and reassuring low-risk patients (46.0–67.7%) (Table 4). Very low levels of
confidence were observed for using the Gail model to calculate breast cancer risk (8.6%).
4.3. Routine Behaviours
The discussion and collection of breast cancer family history was reported to be a
common task (Table 5). Rates were particularly high when the situational context increased
the saliency of the topic matter; for example, during a discussion about a woman’s health
history or when a woman presented with concerns about breast cancer risk (90.4–92.6%).
In comparison, routine collection of family history during a new patient appointment was
found to be lower (48.4–69.3%) in two studies conducted in the UK [42,43]. Reported use
of multi-factorial risk assessment tools was low with estimates ranging from 3 to 50.9%.
Professional specialty and training level were found to be associated with reported
behaviours. A higher proportion of providers specialising in obstetrics and gynaecol-
ogy reported using risk assessment tools in comparison to family and internal medicine
providers [44,45]. Additionally, qualified physicians were significantly more likely to re-
port routinely assessing family history and using the Gail model compared to residents in
training [31,44].
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Table 3. Primary care providers’ perceptions of barriers associated with conducting breast cancer risk assessment.
Themes Percentage Endorsing Barrier [Mean and Range Reported ifMultiple Values] Associations with Barriers
Insufficient education/training [31,41,44,46] 45.2 [20.0–82.1]
Discomfort discussing breast density [35,47,48] 36.9 [11.7–81.5]
Training level:
Internal medicine providers more likely to agree that
they were comfortable counselling women about breast
density compared to primary care residents (38%
compared to 0%) [35]
Discomfort conducting breast cancer risk assessment [46,49,50] 30.9 [29.3–33.5]
Specialty:
Women’s health providers more likely to respond that
they were ‘very comfortable/comfortable’ with using a
breast cancer risk assessment tool compared to other
primary care providers (38% compared to 14%) [46]
More immediate issues to discuss during consultation [31] 25.0
Insufficient provisions to conduct breast cancer risk assessment
effectively (e.g., tools, patient information etc.) [31,41,44,46,51] 20.6 [11.0–40.0]
Perceived lack of impact on patient management [44,46] 16.8 [7.9–25.6]
Low perceived utility and acceptability of genetic testing for
determining breast cancer risk [36,52] 14.0 [5.1–22.9]
Concern that risk prediction models are not accurate enough [51] 13.0
Do not see patients for whom risk assessment is indicated [44,46] 12.5 [7.9–17]
Concern about creating unnecessary anxiety/worry for many
women [51] 7.9 [2.0–13.7]
Assessment of breast cancer risk is not part of routine practice [41] 7.0
Perceived lack of primary care responsibility [46] 5.9
Reluctance to assess risk because a woman at low risk of breast
cancer
might decide not to undergo mammography screening [51]
6.0
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Table 4. Primary care providers’ perceived confidence in performing breast cancer risk assessment behaviours.
Tasks Percentage Reporting Confidence [Mean and RangeReported if Multiple Values] Associations with Confidence
Taking a family history [42,53,54] 63.5 [60.7–65.5]
Training:
Nurses who had attended training about genetic issues in the
12 months were more likely to report being ‘confident or very
confident’ compared with those who did not attend (72%
compared to 59%) [42]
Reassuring low-risk patients [42,53,54] 58.8 [46.0–67.7]
Training:
Confidence providing reassurance for those at low risk of
breast cancer was significantly associated with attending
training about genetic issues [42]
Making a basic risk assessment [42,53] 57.4 [53.9–60.8]
Ability to provide information to patients about BRCA cancer
risks and inheritance [55] 55.8 [50.0–61.6]
Ability to provide information to patients about BRCA test
methods and interpretation [55] 39.6 [37.2–41.9]
Ability to answer patients’ questions during a consultation
about risk [54] 23.2
Ability to use Gail scores to identify women at increased risk
for breast cancer [31] 8.6
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Table 5. Primary care providers’ reported behaviours with respect to breast cancer risk assessment.
Behaviours Percentage Reporting Behaviour [Mean and RangeReported if Multiple Values] Associations with Behaviour
Breast cancer risk assessment
Discussing family history as part of a woman’s health history [56] 92.6
Considering a discussion of family history with a woman consulting
with concerns about breast cancer risk [57] 90.4
Collecting family history during routine clinical practice [31,46,58] 86.3 [71.0–95.0]
Training level:
Staff more likely to report ‘usually or always’ assessing
family history during routine visits compared to
residents (79% compared to 58%) [31]
Discussing family history to assess breast cancer risk [45,49] 67.0 [37.1–96.9]
Collecting family history during new patient appointment [42,43] 58.9 [48.4–69.3]
Using multi-factorial breast cancer risk assessment tools [45,47,50] 33.1 [22.4–50.9]
Specialty:
Obstetric-gynaecologists more likely to report using
breast cancer risk assessment tools compared to family
medicine physicians and internists to (67.2% vs. 44.0%
and 41.7%) [45]
Assessing risk using the Gail model [31,44,49] 16.8 [3.0–40.9]
Training level:
Attending physicians more likely to report use of the Gail
model compared to resident physicians [44]
Specialty:
Gynaecology more likely to report use of the Gail model
compared to family medicine and internal medicine
physicians (60% vs. 33.3% and 36.9%) [44]
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5. Primary Prevention Advice
5.1. Barriers and Facilitators
Overall, there was higher endorsement of barriers for primary prevention than risk as-
sessment. The most prevalent barriers for providing primary prevention advice were
concern and discomfort prescribing risk-reducing medication and insufficient educa-
tion/training, in line with barriers to risk assessment (Table 6). Furthermore, a greater
proportion of primary care providers were more likely to report they see fewer patients for
whom risk-reducing medications are indicated in comparison to patients suitable for risk
assessment (39.6% vs. 12.5%). The majority of primary care providers did not report beliefs
indicating scepticism about the evidence base underpinning risk-reducing medications.
More specifically, few indicated that they believed the risks of prescribing risk-reducing
medications outweighed the benefits (6.5–20.5%) or expressed doubts about effectiveness
of risk-reducing medications (1.0–31.5%). Lack of scepticism was a consistent finding
reported across all five studies that assessed this outcome.
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Table 6. Primary care providers’ perceptions of barriers associated with providing primary prevention advice.
Themes Percentage Endorsing Barrier [Mean and Range Reported ifMultiple Values] Associations with Barriers
Discomfort prescribing risk-reducing medication [44,46] 75.0 [70.1–79.8]
Specialty:
Women’s health providers more likely to respond that
they were ‘very comfortable/comfortable’ with
prescribing risk-reducing medication compared to other
primary care providers (9% compared to 2%) [46]
Concern about prescribing off-label (unlicensed) medication [50] 58.1
Never seen a patient for whom risk-reducing medications are
indicated [44,46] 39.6 [18.4–60.7]
Insufficient education/training [41,46,50,59] 34.6 [13.9–72.0]
Insufficient provisions to discuss risk-reducing measures effectively
(e.g., time, patient information, resources etc.) [41,44,46,50,59,60] 22.7 [6.1–50]
Specialty:
Family and internal medicine physicians more likely to
report time constraints as a barrier than
obstetrician-gynaecologists (45.8% and 46.5% vs. 31.3%,
respectively) [59]
More immediate issues to discuss during consultation [41] 18.0
Doubts about effectiveness of risk-reducing medications (e.g., belief
in ability to reduce risk and mortality, perceiving the evidence base
as controversial) [41,44,45,50,60]
15.4 [1.0–31.5]
Forgetting to discuss risk-reducing medications [41] 14.0
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Table 6. Cont.
Themes Percentage Endorsing Barrier [Mean and Range Reported ifMultiple Values] Associations with Barriers
Believing that the risks of prescribing risk-reducing medications
outweigh the benefits [45,50,60] 13.5 [6.5–20.5]
Specialty:
Obstetrician-gynaecologists less likely to agree that the
evidence of preventive agents reducing breast cancer risk
is controversial compared to family medicine physicians
and internists (22.8% vs. 37.6% and 34.0% respectively)
[45]
Obstetrician-gynaecologists less likely to agree that the
risk of endometrial cancer is too great to prescribe
tamoxifen for breast cancer reduction compared to family
medicine physicians and internists (14.8% vs. 18.4% and
18.8%) [45].
Obstetrician-gynaecologists less likely to agree that the
risk of thromboembolic disease is too great to prescribe
preventive agents for breast cancer reduction compared
to family medicine physicians and internists (10.8% vs.
26.0% and 24.8%) [45]
Women’s perceived lack of interest and knowledge about risk
reduction [41,59] 12.0 [1.0–27.0]
Perceived lack of primary care responsibility [41,46,59] 11.6 [4.0–23.9]
Lack of incentives for discussing risk reducing measures [41,59] 8.3 [3.0–13.6]
Discomfort prescribing a ‘cancer drug’ to healthy women [41] 4.0
Concern about increasing patient’s worry about breast cancer [41] 2.0
Perceived lack of impact on patient management [46] 1.2
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Primary care providers endorsed all facilitators to a relatively high degree (32.0–61.6%;
Table 7). Availability of provisions to discuss risk-reducing options more effectively was
endorsed as the strongest facilitator for providing primary prevention advice.
Table 7. Primary care providers’ perceptions of facilitators associated with providing primary prevention advice.
Themes Percentage Endorsing Facilitator [Mean and Range Reportedif Multiple Values]
Availability of provisions to discuss risk-reducing options more
effectively (e.g., tools and guidelines to identify suitable
patients, better patient education materials etc.) [41,59]
61.6 [33.0–88.0]
Knowing some risk-reducing medications are available at a
Government-subsidised price [41] 54.0
Endorsement as part of role by a professional body [41] 53.0
More education/training [59] 52.0 [34.5–69.4]
Patient has indications of increased breast cancer risk [41] 46.3 [36.0–54.0]
Understanding the benefits of primary prevention [41,59] 44.0 [14.0–59.1]
Peer support [41] 41.7 [27.0–64.0]
Believing that the benefits of preventive agents in breast cancer
outweigh the risks [45,50] 37.6 [12.4–62.8]
Easier to discuss risk-reducing medications than bilateral
mastectomy [41] 32.0
Providers specialising in women’s health reported feeling more comfortable using a
breast cancer risk assessment tool and prescribing risk-reducing medication [46]. These
providers were also less likely to agree that the risks of prescribing risk-reducing medica-
tions outweighed the benefits in comparison to other primary care providers [45].
5.2. Perceived Confidence and Routine Behaviours
Primary care providers reported low levels of confidence in providing advice/information
to patients about risk-reducing medications (24%) [41]. Only one study reported a be-
havioural outcome relevant to primary prevention wherein 13.5% reported discussing
chemoprevention ‘usually’ or ‘always’ [31].
5.3. Quality Assessment
Overall, study quality was poor (Table 8). A detailed breakdown of quality assessment
by question for each study is available in Supplementary Material S3. For the majority of
studies, external validity was likely to be low due to reliance on recruitment through single
institutions and sampling via medical association membership lists with limited coverage
of the target population. For example, membership of the American Medical Association
has been declining with the most recent estimate suggesting only 15% of practising US
doctors are members [61]. Inadequate reporting of how outcome measures were developed
was common across studies. Furthermore, none of the outcomes of interest were assessed
using standardised measures with demonstrated reliability and validity; response rates
lower than 50% were reported in k = 14 (48%) studies [34–37,39,41,45,47,48,50,51,55,58,60].
Cancers 2021, 13, 4150 17 of 23
Table 8. Quality assessment results for studies included in the review (n = 29).
Yes Somewhat No Cannot Tell
n % n % n % n %
Is the sampling strategy relevant to
address the research question? 6 21 17 59 3 10 3 10
Is the sample representative of the target
population? 9 31 5 17 7 24 8 28
Are the measurements appropriate? 0 0 18 62 0 0 11 38
Is the risk of nonresponse bias low? 3 10 11 38 12 41 3 10
Is the statistical analysis appropriate to
answer the research question? 23 79 2 7 0 0 4 14
6. Discussion
6.1. Summary of Main Findings
The results from this systematic review indicate that primary care providers typically
take a reactive role in breast cancer risk assessment that is predominantly focused on
collection of family history and provision of support following identification of increased
risk. Reported use of multi-factorial risk assessment tools was low. Primary care providers
reported higher discomfort and lower confidence with respect to prescribing risk-reducing
medications when compared to risk assessment. However, few providers reported beliefs
suggestive of doubts about the evidence base underpinning risk-reducing medications.
Insufficient education/training and perceived discomfort were amongst the most com-
monly endorsed barriers reported for both activities. The strongest facilitators for offering
risk-reducing medication related to availability of provisions such as clear guidelines and
tools to facilitate identification of suitable patients. Professional background, training
and country were identified as sources of variation in acceptability and behaviours. The
methodological quality of included studies was generally poor and common limitations
were high nonresponse rates and use of non-standardised outcome measures.
6.2. Relevance to Existing Literature
Previous systematic reviews have consistently identified primary care providers’ lack
of knowledge about breast cancer risk assessment and management as a significant barrier
to engagement [19,24,25,62]. In line with this, the present review found that insufficient
education/training was a prevalent barrier reported for both risk assessment and primary
prevention.
Prior to this review, widespread reticence by primary care providers to discuss and
prescribe risk-reducing medications has been recognised [60,63–65]. In line with previous
findings, this review found that primary care providers report high levels of discomfort
and low levels of confidence associated with risk-reducing medications. However, the
present review also offers novel insight: few primary care providers reported scepticism
about the evidence base underpinning risk-reducing medication. This suggests that the
perceived discomfort towards risk-reducing medication is not solely attributable to a lack
of knowledge. The present findings on facilitators instead highlight that there is a need for
more structural approaches, such as the use of guidelines or prompts, to facilitate primary
care involvement in breast cancer risk assessment and management practices.
This review has been the first to investigate sources of variation in acceptability and
behaviours. Examination of routine behaviours illustrated that primary care providers
infrequently report using multi-factorial risk assessments such as the Gail or Tyrer–Cuzick
models [7,8]. Nonetheless, family history collection was reported as a common behaviour
and perceived as a core task for the majority of primary care providers. Lower levels of
routine family history taking were reported by two UK studies [42,43]. However, given the
age of these studies (1997 and 2001), these findings may not be reflective of current clinical
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practice. Nevertheless, present guidelines in the UK and Europe discourage primary care
providers from proactively identifying women with a family history of breast cancer [17,37].
A survey of GPs and breast surgeons from four different European countries revealed
strong disapproval of the current purely reactive approach to family history assessment [66].
Therefore, the present guidelines are likely to hinder optimal promotion of risk assessment
and primary prevention activities in UK and European primary care settings.
Professional background was also associated with outcomes. Providers specialising
in women’s health issues reported feeling more comfortable with respect to both risk
assessment and primary prevention as evidenced by greater reported use of quantitative
risk assessments and fewer negative views about the risks of risk-reducing medications.
These perceptions are likely to be the result of specialised knowledge acquired through
additional training. For instance, an understanding of the diagnosis and clinical man-
agement of hereditary breast and ovarian cancer syndrome is considered essential for
obstetrician/gynaecologists [67]. Therefore, in countries such as the USA, primary care
providers specialising in women’s health may be more prepared to assume greater respon-
sibility for assessment and management of breast cancer risk because of their knowledge
and experience acquired through training and routine practice.
6.3. Limitations
The present review has identified methodological biases present in the primary studies.
Firstly, high rates of nonresponse were observed in a significant proportion of the studies.
Primary care providers who respond to surveys might have more positive views of breast
cancer risk assessment and primary prevention than non-responders which may lead
to overestimations of acceptability. Furthermore, there was a reliance on convenience
sampling procedures in many studies. Outcomes were not assessed using standardised
measures with demonstrated reliability and validity. In addition, older studies included in
the review may be a poor reflection of current clinical practice given the significant advances
made in breast cancer risk assessment and management in recent years. Primary prevention
outcomes tended to be assessed in more recent studies which is in line with risk-reducing
medications being a relatively new option in comparison to risk assessment. Nonetheless,
findings were largely consistent across studies suggesting that methodological limitations
with sampling and publication date did not unduly affect the overall conclusions.
Substantial heterogeneity across included studies was evident and therefore a meta-
analysis was not possible. To allow meaningful patterns to be identified via narrative
synthesis, the research team decided how outcomes were categorised and to some extent
this process was subjective. Nevertheless, analytical processes were reviewed in reflective
team meetings to achieve consensus and ensure a rigorous and robust synthesis.
Additionally, a wide range of values were observed for some outcomes indicating
uncertainty about the average values presented. This is likely to be the result of heteroge-
neous outcome measurements, as well as differences in samples included. Consequently,
caution is warranted when drawing conclusions about the precision of estimating strength
of outcomes.
Finally, and perhaps surprisingly, the review did not identify any studies investigating
primary care providers’ perceptions of discussing health-related behaviours within the
context of breast cancer risk reduction. There is, however, an evidence base focusing
on cancer risk more generally. Inclusion of this literature may have provided a more
comprehensive understanding of primary care’s perceived role in primary prevention than
was possible in this review.
6.4. Implications and Future Research Directions
The present review suggests that provision of education/training will be necessary
but not sufficient to facilitate primary care involvement in breast cancer risk assessment
and primary prevention. The findings on facilitators and routine behaviour indicate that
adapting infrastructure and providing prompts to utilise available resources are essential to
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increase the likelihood of primary care providers routinely conducting both activities. For
instance, the integration of risk assessment and management tools into practice software
or access to web-based applications would facilitate the desired behaviours, as has been
demonstrated for cardiovascular risk assessment and management [20]. Several prototype
tools for breast cancer risk assessment have been subject to usability and acceptability
testing [68,69]. Primary care providers have expressed concerns about the amount of
time needed to complete such tools and highlighted the lack of guidance on clinical
management as a significant barrier to use. Therefore, future tool development should focus
on streamlining the process and incorporating risk reduction recommendations to increase
uptake in routine practice. Additionally, future research should focus on developing and
evaluating the impact of educational interventions on knowledge assimilation. This will
identify what implementation support primary care will require to fulfil their proposed
roles in risk assessment and primary prevention. However, it is worth noting evidence
which suggests not all women may be in favour of primary care performing these roles [70].
Therefore, further research assessing the acceptability of this approach to women is needed.
Nursing staff were underrepresented in the included studies. Decision makers have
suggested that nurses could assume increased duties in risk assessment and management
to support implementation of risk-based screening and prevention [71]. In relation to
primary prevention, general practitioners have been found to perceive intervening on
obesity as an inappropriate use of their time in comparison to nurses who report feeling
responsible for raising the topic [72]. Given the important role of health-related behaviours
in reducing breast cancer risk, it would be timely to compare and contrast the views of
primary care nurses and physicians to determine their respective roles in implementing
prevention recommendations for breast cancer.
Additionally, there is a clear need for more research using populations outside the US
to understand the feasibility of primary care assessing and managing breast cancer risk in
different healthcare contexts. Future primary studies would benefit from assessing similar
outcomes across studies using measures with demonstrated reliability and validity. Wider
and more representative sampling frames should be used to obtain better coverage of the
target population. Furthermore, recruitment strategies that build personal connections
with potential participants such as using physician recruiters ought to be considered to
reduce nonresponse rates [73].
7. Conclusions
Within the context of implementing risk-based breast cancer screening and prevention,
the findings of this review suggest that primary care providers are more likely to accept
an increased role in breast cancer risk assessment compared to advising on risk-reducing
medications. Adaptations to infrastructure will be necessary to promote enactment of
breast cancer risk assessment and management behaviours in addition to provision of
education. To fully realise the benefits of risk-based breast cancer screening and prevention,
guidelines will need to be reviewed to ensure promotion of a proactive approach to breast
cancer risk assessment in primary care.
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